Osteoporosis in Primary Biliary Cholangitis: Prevalence, Impact and Management Challenges

References

• Trivedi HD, Lizaola B, Tapper EB, et al. Primary biliary cholangitis: new treatments for an old disease. Frontline Gastroenterol. 2017;8(1):29–36. doi:10.1136/flgastro-2016-100741
   Web of Science ®Google Scholar
• Lee JY, Danford CJ, Trivedi HD, et al. Treatment of fatigue in primary biliary cholangitis: a systematic review and meta-analysis. Dig Dis Sci. 2019. doi:10.1007/s10620-019-5457-5
   Web of Science ®Google Scholar
• Trivedi HD, Lizaola B, Tapper EB, et al. Management of pruritus in primary biliary cholangitis: a narrative review. Am J Med. 2017;130:744.e1–744.e7. doi:10.1016/j.amjmed.2017.01.037
   Web of Science ®Google Scholar
• Danford CJ, Ezaz G, Trivedi HD, et al. The pharmacologic management of osteoporosis in primary biliary cholangitis: a systematic review and meta-analysis. J Clin Densitom. 2019. doi:10.1016/j.jocd.2019.05.003
   Web of Science ®Google Scholar
• Reshetnyak VI. Concept on the pathogenesis and treatment of primary biliary cirrhosis. World J Gastroenterol. 2006;12(45):7250–7262. doi:10.3748/wjg.v12.i45.7250
   Web of Science ®Google Scholar
• Hay JE. Bone disease in cholestatic liver disease. Gastroenterology. 1995;108(1):276–283. doi:10.1016/0016-5085(95)90033-0
   Web of Science ®Google Scholar
• Guanabens N, Parés A, Ros I, et al. Severity of cholestasis and advanced histological stage but not menopausal status are the major risk factors for osteoporosis in primary biliary cirrhosis. J Hepatol. 2005;42(4):573–577. doi:10.1016/j.jhep.2004.11.035
   Web of Science ®Google Scholar
• Guanabens N, Cerdá D, Monegal A, et al. Low bone mass and severity of cholestasis affect fracture risk in patients with primary biliary cirrhosis. Gastroenterology. 2010;138(7):2348–2356. doi:10.1053/j.gastro.2010.02.016
   Web of Science ®Google Scholar
• Cohen SM, Te HS, Levitsky J. Operative risk of total hip and knee arthroplasty in cirrhotic patients. J Arthroplasty. 2005;20(4):460–466. doi:10.1016/j.arth.2004.05.004
   Web of Science ®Google Scholar
• Guanabens N, Parés A, Mariñoso L, et al. Factors influencing the development of metabolic bone disease in primary biliary cirrhosis. Am J Gastroenterol. 1990;85(10):1356–1362.
   Web of Science ®Google Scholar
• Office of the Surgeon, G. Reports of the Surgeon General, in Bone Health and Osteoporosis: A Report of the Surgeon General. Rockville (MD): Office of the Surgeon General (US); 2004.
   Google Scholar
• Kim WR, Lindor KD, Locke GR, et al. Epidemiology and natural history of primary biliary cirrhosis in a US community. Gastroenterology. 2000;119(6):1631–1636. doi:10.1053/gast.2000.20197
   PubMed Web of Science ®Google Scholar
• Hurlburt KJ, McMahon BJ, Deubner H, et al. Prevalence of autoimmune liver disease in Alaska natives. Am J Gastroenterol. 2002;97(9):2402–2407. doi:10.1111/j.1572-0241.2002.06019.x
   Web of Science ®Google Scholar
• Boonstra K, Beuers U, Ponsioen CY. Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review. J Hepatol. 2012;56(5):1181–1188. doi:10.1016/j.jhep.2011.10.025
   PubMed Web of Science ®Google Scholar
• Lu M, Zhou Y, Haller IV, et al. Increasing prevalence of primary biliary cholangitis and reduced mortality with treatment. Clin Gastroenterol Hepatol. 2018;16(8):1342–1350.e1. doi:10.1016/j.cgh.2017.12.033
   PubMed Web of Science ®Google Scholar
• Moon AM, Singal AG, Tapper EB. Contemporary epidemiology of chronic liver disease and cirrhosis. Clin Gastroenterol Hepatol. 2019. doi:10.1016/j.cgh.2019.07.060
   Web of Science ®Google Scholar
• Danford CJ, Trivedi HD, Papamichael K, et al. Osteoporosis in primary biliary cholangitis. World J Gastroenterol. 2018;24(31):3513–3520. doi:10.3748/wjg.v24.i31.3513
   PubMed Web of Science ®Google Scholar
• Menon KV, Angulo P, Weston S, et al. Bone disease in primary biliary cirrhosis: independent indicators and rate of progression. J Hepatol. 2001;35(3):316–323. doi:10.1016/S0168-8278(01)00144-1
   PubMed Web of Science ®Google Scholar
• Guanabens N, Parés A, Navasa M, et al. Cyclosporin A increases the biochemical markers of bone remodeling in primary biliary cirrhosis. J Hepatol. 1994;21(1):24–28. doi:10.1016/S0168-8278(94)80132-0
   Web of Science ®Google Scholar
• Newton J, Francis R, Prince M, et al. Osteoporosis in primary biliary cirrhosis revisited. Gut. 2001;49(2):282–287. doi:10.1136/gut.49.2.282
   Web of Science ®Google Scholar
• Guichelaar MM, Kendall R, Malinchoc M, et al. Bone mineral density before and after OLT: long-term follow-up and predictive factors. Liver Transpl. 2006;12(9):1390–1402. doi:10.1002/(ISSN)1527-6473
   PubMed Web of Science ®Google Scholar
• Seki A, Ikeda F, Miyatake H, et al. Risk of secondary osteoporosis due to lobular cholestasis in non-cirrhotic primary biliary cholangitis. J Gastroenterol Hepatol. 2017;32(9):1611–1616. doi:10.1111/jgh.2017.32.issue-9
   Web of Science ®Google Scholar
• Pares A, Guañabens N, Alvarez L, et al. Collagen type Ialpha1 and vitamin D receptor gene polymorphisms and bone mass in primary biliary cirrhosis. Hepatology. 2001;33(3):554–560. doi:10.1053/jhep.2001.22758
   Web of Science ®Google Scholar
• Guichelaar MM, Malinchoc M, Sibonga JD, et al. Bone histomorphometric changes after liver transplantation for chronic cholestatic liver disease. J Bone Miner Res. 2003;18(12):2190–2199. doi:10.1359/jbmr.2003.18.12.2190
   Web of Science ®Google Scholar
• Eastell R, Dickson ER, Hodgson SF, et al. Rates of vertebral bone loss before and after liver transplantation in women with primary biliary cirrhosis. Hepatology. 1991;14(2):296–300. doi:10.1002/(ISSN)1527-3350
   Web of Science ®Google Scholar
• Bjoro K, Brandsæter B, Wiencke K, et al. Secondary osteoporosis in liver transplant recipients: a longitudinal study in patients with and without cholestatic liver disease. Scand J Gastroenterol. 2003;38(3):320–327. doi:10.1080/00365520310000681a
   PubMed Web of Science ®Google Scholar
• Haagsma EB, Thijn CJP, Post JG, et al. Bone disease after orthotopic liver transplantation. J Hepatol. 1988;6(1):94–100. doi:10.1016/S0168-8278(88)80467-7
   Web of Science ®Google Scholar
• Meys E, Fontanges E, Fourcade N, et al. Bone loss after orthotopic liver transplantation. Am J Med. 1994;97(5):445–450. doi:10.1016/0002-9343(94)90324-7
   Web of Science ®Google Scholar
• Butin S, Griffoul I, Espitalier F, et al. High incidence of vertebral osteoporotic fracture within the first year after liver transplantation. Clin Exp Rheumatol. 2017;35(6):913–918.
   Google Scholar
• Lindor KD, Gershwin ME, Poupon R, et al. Primary biliary cirrhosis. Hepatology. 2009;50(1):291–308. doi:10.1002/hep.22906
   PubMed Web of Science ®Google Scholar
• Reshetnyak VI. Primary biliary cirrhosis: clinical and laboratory criteria for its diagnosis. World J Gastroenterol. 2015;21(25):7683–7708. doi:10.3748/wjg.v21.i25.7683
   Web of Science ®Google Scholar
• Glass LM, Su GL. Metabolic bone disease in primary biliary cirrhosis. Gastroenterol Clin North Am. 2016;45(2):333–343. doi:10.1016/j.gtc.2016.02.009
   Web of Science ®Google Scholar
• Pares A, Guanabens N. Osteoporosis in primary biliary cirrhosis: pathogenesis and treatment. Clin Liver Dis. 2008;12(2):407–24; x. doi:10.1016/j.cld.2008.02.005
   Web of Science ®Google Scholar
• Bernstein CN, Leslie WD, Leboff MS. AGA technical review on osteoporosis in gastrointestinal diseases. Gastroenterology. 2003;124(3):795–841. doi:10.1053/gast.2003.50106
   Web of Science ®Google Scholar
• Cosman F, de Beur SJ, LeBoff MS, et al. Clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int. 2014;25(10):2359–2381. doi:10.1007/s00198-014-2794-2
   PubMed Web of Science ®Google Scholar
• Kemmler W, Engelke K, von Stengel S. Long-term exercise and bone mineral density changes in postmenopausal women–are there periods of reduced effectiveness? J Bone Miner Res. 2016;31(1):215–222. doi:10.1002/jbmr.2608
   Web of Science ®Google Scholar
• Trivedi HD, Tapper EB. Interventions to improve physical function and prevent adverse events in cirrhosis. Gastroenterol Rep (Oxf). 2018;6(1):13–20. doi:10.1093/gastro/gox042
   Web of Science ®Google Scholar
• Poupon RE, Bonnand A-M, Chrétien Y, et al. Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis. The UDCA-PBC Study Group. Hepatology. 1999;29(6):1668–1671. doi:10.1002/hep.510290603
   PubMed Web of Science ®Google Scholar
• Pares A, Caballería L, Rodés J, et al. Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. UDCA-Cooperative Group from the Spanish Association for the Study of the Liver. J Hepatol. 2000;32(4):561–566. doi:10.1016/S0168-8278(00)80216-0
   Web of Science ®Google Scholar
• Nevens F, Andreone P, Mazzella G, et al. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N Engl J Med. 2016;375(7):631–643. doi:10.1056/NEJMoa1509840
   PubMed Web of Science ®Google Scholar
• Levy C, Peter JA, Nelson DR, et al. Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. Aliment Pharmacol Ther. 2011;33(2):235–242. doi:10.1111/j.1365-2036.2010.04512.x
   PubMed Web of Science ®Google Scholar
• Reig A, Sese P, Pares A. Bezafibrate: a novel and effective alternative for relieving pruritus in patients with primary biliary cirrhosis. Hepatology. 2015;62:508A.
   Web of Science ®Google Scholar
• Lindor KD, Janes CH, Crippin JS, et al. Bone disease in primary biliary cirrhosis: does ursodeoxycholic acid make a difference? Hepatology. 1995;21(2):389–392.
   Web of Science ®Google Scholar
• Shiomi S, Masaki K, Habu D, et al. Calcitriol for bone loss in patients with primary biliary cirrhosis. J Gastroenterol. 1999;34(2):241–245. doi:10.1007/s005350050250
   Web of Science ®Google Scholar
• Lindor KD, Bowlus CL, Boyer J, et al. Primary biliary cholangitis: 2018 practice guidance from the American Association for the study of liver diseases. Hepatology. 2019;69(1):394–419. doi:10.1002/hep.30145
   PubMed Web of Science ®Google Scholar
• EASL. EASL Clinical practice guidelines: the diagnosis and management of patients with primary biliary cholangitis. J Hepatol. 2017;67(1):145–172. doi:10.1016/j.jhep.2017.03.022
   Web of Science ®Google Scholar
• Hillard TC, Whitcroft SJ, Marsh MS, et al. Long-term effects of transdermal and oral hormone replacement therapy on postmenopausal bone loss. Osteoporos Int. 1994;4(6):341–348. doi:10.1007/BF01622195
   Web of Science ®Google Scholar
• Olsson R,Mattsson LÅ, Obrant K, Mellström D. Estrogen-progestogen therapy for low bone mineral density in primary biliary cirrhosis. Liver. 1999;19(3):188–192. doi:10.1111/j.1478-3231.1999.tb00034.x
   Google Scholar
• Menon KV, Angulo P, Boe GM, et al. Safety and efficacy of estrogen therapy in preventing bone loss in primary biliary cirrhosis. Am J Gastroenterol. 2003;98(4):889–892. doi:10.1111/j.1572-0241.2003.07341.x
   PubMed Web of Science ®Google Scholar
• Ormarsdottir S, Mallmin H, Naessén T, et al. An open, randomized, controlled study of transdermal hormone replacement therapy on the rate of bone loss in primary biliary cirrhosis. J Intern Med. 2004;256(1):63–69. doi:10.1111/j.1365-2796.2004.01342.x
   Web of Science ®Google Scholar
• Boone RH, Cheung AM, Girlan LM, et al. Osteoporosis in primary biliary cirrhosis: a randomized trial of the efficacy and feasibility of estrogen/progestin. Dig Dis Sci. 2006;51(6):1103–1112. doi:10.1007/s10620-006-8015-x
   Web of Science ®Google Scholar
• Zein CO, Jorgensen RA, Clarke B, et al. Alendronate improves bone mineral density in primary biliary cirrhosis: a randomized placebo-controlled trial. Hepatology. 2005;42(4):762–771. doi:10.1002/(ISSN)1527-3350
   PubMed Web of Science ®Google Scholar
• Lindor KD, Jorgensen RA, Tiegs RD, et al. Etidronate for osteoporosis in primary biliary cirrhosis: a randomized trial. J Hepatol. 2000;33(6):878–882. doi:10.1016/S0168-8278(00)80118-X
   Web of Science ®Google Scholar
• Wolfhagen FH, van Buuren HR, den Ouden JW, et al. Cyclical etidronate in the prevention of bone loss in corticosteroid-treated primary biliary cirrhosis. A prospective, controlled pilot study. J Hepatol. 1997;26(2):325–330. doi:10.1016/S0168-8278(97)80048-7
   Web of Science ®Google Scholar
• Levy C, Harnois DM, Angulo P, et al. Raloxifene improves bone mass in osteopenic women with primary biliary cirrhosis: results of a pilot study. Liver Int. 2005;25(1):117–121. doi:10.1111/liv.2005.25.issue-1
   PubMed Web of Science ®Google Scholar
• Camisasca M, Battezzati PM, Albisetti W, et al. Parenteral calcitonin for metabolic bone disease associated with primary biliary cirrhosis. Hepatology. 1994;20(3):633–637. doi:10.1016/0270-9139(94)90098-1
   Web of Science ®Google Scholar
• Floreani A, Zappala F, Fries W, et al. A 3-year pilot study with 1,25-dihydroxyvitamin D, calcium, and calcitonin for severe osteodystrophy in primary biliary cirrhosis. J Clin Gastroenterol. 1997;24(4):239–244. doi:10.1097/00004836-199706000-00012
   PubMed Web of Science ®Google Scholar
• Guanabens N, Parés A, Del Rio L, et al. Sodium fluoride prevents bone loss in primary biliary cirrhosis. J Hepatol. 1992;15(3):345–349. doi:10.1016/0168-8278(92)90066-X
   Web of Science ®Google Scholar
• Guanabens N, Pares A, Monegal A, et al. Etidronate versus fluoride for treatment of osteopenia in primary biliary cirrhosis: preliminary results after 2 years. Gastroenterology. 1997;113(1):219–224. doi:10.1016/S0016-5085(97)70098-2
   Web of Science ®Google Scholar
• Nishiguchi S, Shimoi S, Kurooka H, et al. Randomized pilot trial of Vitamin K2 for bone loss in patients with primary biliary cirrhosis. J Hepatol. 2001;35(4): 543–545.
   Web of Science ®Google Scholar
• Dresner-Pollak R, Gabet Y, Steimatzky A, et al. Human parathyroid hormone 1-34 prevents bone loss in experimental biliary cirrhosis in rats. Gastroenterology. 2008;134(1):259–267. doi:10.1053/j.gastro.2007.10.025
   Web of Science ®Google Scholar